Additionally, the multidrug transporter ABCG2 has been shown to be downregulated following PDT in orthotopic in vivo models of pancreatic cancer, leading to increased irinotecan retention and therapeutic efficacy [9]. This evidence concerns the gene ABCG2 and familial pancreatic carcinoma.